BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 38067299)

  • 1. Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.
    Marrone G; Leone MS; Biolato M; Liguori A; Bianco G; Spoletini G; Gasbarrini A; Miele L; Pompili M
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation.
    Pelizzaro F; Gambato M; Gringeri E; Vitale A; Cillo U; Farinati F; Burra P; Russo FP
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.
    Yang PC; Ho CM; Hu RH; Ho MC; Wu YM; Lee PH
    World J Hepatol; 2016 Nov; 8(31):1309-1317. PubMed ID: 27872682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
    Degroote H; Piñero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
    JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma.
    Sposito C; Cucchetti A; Mazzaferro V
    Dig Dis Sci; 2019 Apr; 64(4):1001-1007. PubMed ID: 30852770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.
    Pompili M; Francica G; Ponziani FR; Iezzi R; Avolio AW
    World J Gastroenterol; 2013 Nov; 19(43):7515-30. PubMed ID: 24282343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma.
    Tabrizian P; Holzner ML; Mehta N; Halazun K; Agopian VG; Yao F; Busuttil RW; Roberts J; Emond JC; Samstein B; Brown RS; Najjar M; Chapman WC; Doyle MM; Florman SS; Schwartz ME; Llovet JM
    JAMA Surg; 2022 Sep; 157(9):779-788. PubMed ID: 35857294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of post-transplantation recurrence of hepatocellular carcinoma.
    Rajendran L; Ivanics T; Claasen MP; Muaddi H; Sapisochin G
    Clin Mol Hepatol; 2022 Jan; 28(1):1-16. PubMed ID: 34610652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
    Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
    Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-Transplant Factors Influencing Rates of Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients.
    Zucker KM; Gomez PA; Kezirian O; Mehta S
    Gastroenterology Res; 2021 Jun; 14(3):190-193. PubMed ID: 34267835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence.
    Rahimi RS; Trotter JF
    Ann Gastroenterol; 2015; 28(3):323-330. PubMed ID: 26130250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review.
    Muhammad H; Tehreem A; Ting PS; Gurakar M; Li SY; Simsek C; Alqahtani SA; Kim AK; Kohli R; Gurakar A
    J Clin Transl Hepatol; 2021 Oct; 9(5):738-748. PubMed ID: 34722189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
    Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
    Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation.
    Ogawa K; Takada Y
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
    Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
    BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of hepatocellular carcinoma following liver transplantation.
    Hoffman D; Mehta N
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):91-102. PubMed ID: 32933351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
    Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
    Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors in liver transplant: a case series.
    Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
    J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation for hepatocellular carcinoma: Management after the transplant.
    Verna EC; Patel YA; Aggarwal A; Desai AP; Frenette C; Pillai AA; Salgia R; Seetharam A; Sharma P; Sherman C; Tsoulfas G; Yao FY
    Am J Transplant; 2020 Feb; 20(2):333-347. PubMed ID: 31710773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.